Original article—liver, pancreas, and biliary tractAssessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases
Section snippets
Patients
We prospectively recruited consecutive adult patients with chronic liver diseases who were clinically indicated for liver biopsy examination in our hospital in 12 months from July 2006–June 2007. The indications of liver biopsy were identifying the etiology of liver disease and assessing the severity of liver fibrosis and inflammation before treatment. We excluded patients who were chronic drinkers (with regular consumption of at least 20 g of alcohol weekly), and who had decompensated liver
Patients
One hundred eighty-two patients underwent liver biopsy within the study period; 133 (73%) patients fulfilled the criteria for data analysis. Thirty-seven patients were excluded because of inadequate liver biopsy samples size (<1.5 cm and/or <6 portal tracts), 10 patients were excluded because of unsuccessful LSM (3 patients were overweight and 6 patients were obese), and 2 patients were excluded for both reasons (both patients were obese). Overall, 38 of the 182 patients (21%) had a BMI ≥28 kg/m
Discussion
In this study, we demonstrated that LSM with transient elastography (Fibroscan) had good correlation with histologic liver fibrosis in patients with chronic liver diseases. With morphometric analysis, we showed that LSM correlated better with pericellular fibrosis than periportal or perivenular fibrosis. This phenomenon might explain why LSM is accurate in detecting bridging fibrosis and cirrhosis but not milder degree of liver fibrosis. LSM tends to overestimate the liver fibrosis in patients
References (42)
- et al.
Metabolic and adipokine profile of Chinese patients with non-alcoholic fatty liver disease
Clin Gastroenterol Hepatol
(2006) - et al.
American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease
Gastroenterology
(2006) - et al.
Sampling variability of liver fibrosis in chronic hepatitis C
Hepatology
(2003) - et al.
Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis
J Hepatol
(1999) - et al.
Noninvasive diagnosis of hepatic fibrosis or cirrhosis
Gastroenterology
(1997) - et al.
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
Hepatology
(2003) - et al.
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
Lancet
(2001) - et al.
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
Hepatology
(2002) - et al.
Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
Gastroenterology
(2005) - et al.
Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients
J Hepatol
(2007)
An algorithm for grading of activity in chronic hepatitis C
Hepatology
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
Am J Gastroenterol
Transient elastography: a new noninvasive method for assessment of hepatic fibrosis
Ultrasound Med Biol
Histological progression of nonalcoholic fatty liver disease in Chinese patients
Aliment Pharmacol Ther
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
Liver Int
Chronic hepatitis B
Hepatology
Liver biopsy
N Engl J Med
Pain experienced during percutaneous liver biopsy
Hepatology
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C
Hepatology
Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model
Am J Gastroenterol
Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study
Clin Chem
Cited by (132)
Ultrasound Evaluation of Liver Fibrosis
2017, Journal of Medical UltrasoundTechnical Success, Sample Adequacy, and Complications of Pediatric Transjugular Liver Biopsy: A Systematic Review and Meta-Analysis
2023, Digestive Diseases and SciencesLong-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
2023, Clinical and Molecular HepatologyValidation and Performance of FibroScan®-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease
2022, Digestive Diseases and Sciences
Dr Francis K. L. Chan received an independent research grant and a consulting fee from Pfizer and paid lecture fees by TAP Pharmaceuticals. Dr Joseph J. Y. Sung received consulting fees from the National Health Research Institutes of Taipei, The Hong Kong Police Force, Lippincott Williams & Wilkins, and the Hong Kong College of Physicians and paid lecture fees by AstraZeneca Hong Kong Limited, GSK Pharmaceuticals International, and the American Society for Gastrointestinal Endoscopy. Dr Henry L. Y. Chan is a member of the advisory boards of Novartis and Schering-Plough.